EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study

Eloïse Gallo, Philippe Gaudard iD, Sophie Provenchère, Fouzia Souab, Anaïs Schwab, Damien Bedague, Hugues de La Barre, Christian de Tymowski, Laysa Saadi, Bertrand Rozec, Bernard Cholley, Bruno Scherrer und 3 weitere

European Journal of Cardio-Thoracic Surgery · 2024

DOI: 10.1093/ejcts/ezae001 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2024. Verfasst von Eloïse Gallo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Anaesthesia and Critical Care, CHU Bordeaux, France. Hauptthemen laut MEDLINE: Aprotinin, Blood Loss, Surgical, Cardiac Surgical Procedures, Tranexamic Acid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: French Society of Cardiovascular and Thoracic Anaesthesiologists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES Following the reintroduction of aprotinin into the European market, the French Society of Cardiovascular and Thoracic Anaesthesiologists recommended its prophylactic use at half-dose for high-risk cardiac surgery patients. We examined whether the use of aprotinin instead of tranexamic acid could significantly reduce severe perioperative bleeding. METHODS This multicentre, retrospective, historical study included cardiac surgery patients treated with aprotinin or tranexamic acid between December 2017 and September 2020. The primary efficacy end point was the severe or massive perioperative bleeding (class 3–4 of the universal definition of perioperative bleeding). The safety secondary end points included the occurrence of thromboembolic events and all-cause mortality within 30 days after surgery. RESULTS Among the 693 patients included in the study, 347 received aprotinin and 346 took tranexamic acid. The percentage of patients with severe or massive bleeding was similar in the 2 groups (42.1% vs 43.6%, Adjusted odds ratio [ORadj] = 0.87, 95% confidence interval: 0.62–1.23, P = 0.44), as was the perioperative need for blood products (81.0% vs 83.2%, ORadj = 0.75, 95% confidence interval: 0.48–1.17, P = 0.20). However, the median (Interquartile range) 12 h postoperative blood loss was significantly lower in the aprotinin group (383 ml [241–625] vs 450 ml [290–730], P < 0.01). Compared to tranexamic acid, the intraoperative use of aprotinin was associated with increased risk for thromboembolic events (adjusted Hazard ratio 2.30 [95% Cl: 1.06–5.30]; P = 0.04). CONCLUSIONS Given the modest reduction in blood loss at the expense of a significant increase in thromboembolic adverse events, aprotinin use in high-risk cardiac surgery patients should be based on a carefully considered benefit–risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AprotininBlood Loss, SurgicalCardiac Surgical ProceduresTranexamic AcidHumansAntifibrinolytic AgentsAPACHEHemostaticsRetrospective Studies

Stichwörter der Autor:innen

AntifibrinolyticCardiac surgeryPerioperative bleeding

Substanzen

Antifibrinolytic AgentsAprotininHemostaticsTranexamic Acid

Autor:innen und Institutionen

  • Department of Cardiovascular Anaesthesia and Critical Care, CHU Bordeaux, France.
  • Department of Anaesthesia and Critical Care, Arnaud de Villeneuve Hospital, Montpellier, France.
  • Department of Anaesthesia and Critical Care, Bichat Claude Bernard Hospital, Paris, France.
  • Department of Anaesthesia and Critical Care, Hôpital Laennec, CHU Nantes, France.
  • Department of Anaesthesia and Critical Care, Hospices Civils de Lyon, France.
  • Department of Anaesthesia and Critical Care, Grenoble-Alpes University Hospital, France.

ORCID-Profile: Philippe Gaudard, Alexandre Ouattara

Förderung

  • French Society of Cardiovascular and Thoracic Anaesthesiologists

Zitieren

APA

Gallo, E., Gaudard, P., Provenchère, S., Souab, F., Schwab, A., Bedague, D., de La Barre, H., de Tymowski, C., Saadi, L., Rozec, B., Cholley, B., Scherrer, B., Fellahi, J. L., Ouattara, A., & APACHE investigators (2024). Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezae001

Vancouver

Gallo E, Gaudard P, Provenchère S, Souab F, Schwab A, Bedague D, et al. Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study. European Journal of Cardio-Thoracic Surgery. 2024. doi:10.1093/ejcts/ezae001

BibTeX
@article{Gallo2024,
  author = {Gallo, Eloïse and Gaudard, Philippe and Provenchère, Sophie and Souab, Fouzia and Schwab, Anaïs and Bedague, Damien and de La Barre, Hugues and de Tymowski, Christian and Saadi, Laysa and Rozec, Bertrand and Cholley, Bernard and Scherrer, Bruno and Fellahi, Jean-Luc and Ouattara, Alexandre and APACHE investigators, APACHE investigators},
  title = {Use of Aprotinin versus Tranexamic Acid in Cardiac Surgery Patients with High-Risk for Excessive Bleeding (APACHE) trial: a multicentre retrospective comparative non-randomized historical study},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2024},
  doi = {10.1093/ejcts/ezae001}
}
Kostenlos starten →